Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse CancersAaron M. Goodman, Razelle Kurzrock, Shumei Kato et al.|Molecular Cancer Therapeutics|2017Cited by 2.4k
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trialAssuntina G. Sacco, Ezra E.W. Cohen, Ruifeng Chen et al.|The Lancet Oncology|2021Cited by 257
Hypermutated Circulating Tumor DNA: Correlation with Response to Checkpoint Inhibitor–Based ImmunotherapyYulian Khagi, Razelle Kurzrock, Aaron M. Goodman et al.|Clinical Cancer Research|2017Cited by 202
Next generation sequencing of cell free circulating tumor DNA in blood samples of recurrent and metastatic head and neck cancer patientsAshleigh Porter, Ezra E.W. Cohen, Mandy Natsuhara et al.|Translational Cancer Research|2020Cited by 28